December 8, 2023

The combination of venetoclax and selinexor alongside chemotherapy was well-tolerated in patients with relapsed or refractory acute myeloid leukemia in a recent data analysis of a phase 1 study. Children and adolescents/young adults with relapsed or refractory acute myeloid leukemia (R/R AML) continue to have poor survival rates. In children with R/R AML, prior clinical...

Selinexor in combination with venetoclax and azacitidine (the SAV regimen) is safe and effective, with encouraging complete response rates, according to a recent prospective study. Acute myeloid leukemia (AML) primarily affects older people, who are frequently unable to endure intense chemotherapy due to frailty or comorbid conditions. While venetoclax with azacytidine has a 64% response...

 Variations in the degree of venous malformation tissue involvement and thrombin–antithrombin complex/D-dimer correlation could point to a coagulopathy progressing proportionally to the degree of VM, according to a retrospective study. Although poorly understood, localized intravascular coagulopathy (LIC) is a known consequence of venous malformations (VMs) that can cause thrombosis, bleeding, and the development of phleboliths....